Cancer Research · 2009 · 35 citations · 0 references
MedicineOncologyPharmacologyBreast OncologyChemotherapyMolecular OncologyAdjuvant ChemotherapyAdjuvant TherapyBreast Cancer RecurrenceBreast Cancer Risk AssessmentCancer Survival AnalysisHormonal Cancer TherapyAdjuvant Clinical TrialsAdjuvant Hormonal TherapyAdjuvant UseAromatase InhibitorsBreast Cancer PrognosisRecurrenceResidual RiskResidual Risk Identification
Abstract Abstract #53 Background: The Recurrence Score (RS) has been validated for estimating residual risk of distant recurrence (DR) in ER+ node negative (N-) primary breast cancer patients receiving adjuvant tamoxifen. Aromatase inhibitors (AIs) are widely used for adjuvant treatment of ER+ disease in postmenopausal women. The RS has not been evaluated in patients treated with an AI.
 Method: Tumour blocks were collected retrospectively from patients in the monotherapy arms of the ATAC trial under the TransATAC protocol yielding 1308 hormone receptor positive (HR+) blocks in UK patients for analysis (1). Cox proportional hazards model was used to test the significance of adding RS to a clinical model (age, tumour size, grade, treatment) and to Adjuvant! Online.
 Results: 65 patients received chemotherapy, 4 were centrally HR negative and 8 did not start adjuvant therapy leaving 1231 evaluable patients of which 872, 306 and 53 were N-, N+ and N unknown in whom there were 72, 74 and 6 DRs, respectively. In the prospectively-defined primary multivariate analysis tumour size, grade and RS were each separately statistically significant in predicting time to DR in N- patients (p<0.001, 0.003 and <0.001, respectively). Similar results were seen in N+ patients. The 9-year rates of DR by nodal status for the pre-specified RS groups are shown in the table. RS showed statistically significant prognostic value beyond that provided by Adjuvant! Online in both N- (p<0.001) and N+ patients (p=0.003).
 
 Conclusions: Oncotype DX RS is an independent predictor of the risk of distant recurrence in N- and N+ HR+ patients treated with anastrozole or tamoxifen. The data are not predictive of a differential benefit between anastrozole and tamoxifen.
 (1) Dowsett et al JCO 2008, 26, 1059. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 53.